Daniel Ajona

Daniel Ajona

UNVERIFIED PROFILE

Are you Daniel Ajona?   Register this Author

Register author
Daniel Ajona

Daniel Ajona

Publications by authors named "Daniel Ajona"

Are you Daniel Ajona?   Register this Author

26Publications

320Reads

-Profile Views

Targeting of TMPRSS4 sensitizes lung cancer cells to chemotherapy by impairing the proliferation machinery.

Cancer Lett 2019 Jul 21;453:21-33. Epub 2019 Mar 21.

IDISNA and Program in Solid Tumors, Center for Applied Medical Research (CIMA), University of Navarra, 31008, Pamplona, Navarra, Spain; Department of Pathology, Anatomy and Physiology, School of Medicine, University of Navarra, 31008, Pamplona, Navarra, Spain; CIBERONC, ISC-III, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2019.03.013DOI Listing
July 2019

The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma.

Clin Cancer Res 2019 May 28;25(10):3176-3187. Epub 2019 Jan 28.

Clinica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), CIBER-ONC number CB16/12/00369 and CB16/12/00489, Pamplona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-1597DOI Listing
May 2019

Complement in Metastasis: A Comp in the Camp.

Front Immunol 2019 3;10:669. Epub 2019 Apr 3.

Program in Solid Tumors, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.

View Article

Download full-text PDF

Source
https://www.frontiersin.org/article/10.3389/fimmu.2019.00669
Publisher Site
http://dx.doi.org/10.3389/fimmu.2019.00669DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6457318PMC
April 2019

Complementing the Cancer-Immunity Cycle.

Front Immunol 2019 12;10:774. Epub 2019 Apr 12.

Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2019.00774DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6473060PMC
April 2019

Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges.

J Thorac Oncol 2019 Mar 4;14(3):343-357. Epub 2018 Dec 4.

Solid Tumors Program, Centro de Investigación Médica Aplicada, Pamplona, Spain; Navarra Institute for Health Research, Pamplona, Spain; CIBERONC, Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain; Department of Pathology, Anatomy and Physiology, School of Medicine, University of Navarra, Pamplona, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.11.023DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6494979PMC
March 2019

Complement anaphylatoxins C3a and C5a: Emerging roles in cancer progression and treatment.

Semin Cell Dev Biol 2019 01 23;85:153-163. Epub 2017 Nov 23.

University of Navarra, Center for Applied Medical Research (CIMA), Program in Solid Tumors and Biomarkers, Pamplona, Spain; Navarra's Health Research Institute (IdiSNA), Pamplona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain; University of Navarra, School of Sciences, Department of Biochemistry and Genetics, Pamplona, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semcdb.2017.11.023DOI Listing
January 2019

Radiation effects on antitumor immune responses: current perspectives and challenges.

Ther Adv Med Oncol 2018 18;10:1758834017742575. Epub 2018 Jan 18.

Programme in Solid Tumours and Biomarkers, Division of Oncology, Centre for Applied Biomedical Research (CIMA), IdiSNA, Navarra Institute for Health Research, Department of Histology and Pathology, University of Navarra, School of Medicine, Pamplona, Spain. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1758834017742575DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5784573PMC
January 2018

Complement C4d-specific antibodies for the diagnosis of lung cancer.

Oncotarget 2018 Jan 26;9(5):6346-6355. Epub 2017 Dec 26.

Program in Solid Tumors, Center for Applied Medical Research (CIMA), CIBERONC, and Navarra's Health Research Institute (IDISNA), Pamplona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.23690DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814217PMC
January 2018

A large-scale analysis of alternative splicing reveals a key role of QKI in lung cancer.

Mol Oncol 2016 11 9;10(9):1437-1449. Epub 2016 Aug 9.

Program in Solid Tumors and Biomarkers, CIMA, 31008 Pamplona, Spain; Department of Biochemistry and Genetics, School of Science, University of Navarra, 31008 Pamplona, Spain; Navarra's Health Research Institute (IDISNA), 31008 Pamplona, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molonc.2016.08.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5423218PMC
November 2016

Innate immune mediators in cancer: between defense and resistance.

Immunol Rev 2016 11;274(1):290-306

Navarra Institute for Health Research (IDISNA), Pamplona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/imr.12464DOI Listing
November 2016

Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti-PD-1 and Anti-CD137 Monoclonal Antibodies.

J Thorac Oncol 2016 Apr 1;11(4):524-36. Epub 2016 Feb 1.

Department of Immunology, Center for Applied Medical Research, Universidad de Navarra; Department of Oncology and Clinical Trial Unit, Clínica Universidad de Navarra. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2016.01.013DOI Listing
April 2016

Elevated levels of the complement activation product C4d in bronchial fluids for the diagnosis of lung cancer.

PLoS One 2015 23;10(3):e0119878. Epub 2015 Mar 23.

Program in Solid Tumors and Biomarkers, Center for Applied Medical Research (CIMA), Pamplona, Spain; Department of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Spain.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0119878PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4370816PMC
March 2016

Investigation of complement activation product c4d as a diagnostic and prognostic biomarker for lung cancer.

J Natl Cancer Inst 2013 Sep 12;105(18):1385-93. Epub 2013 Aug 12.

Affiliations of authors: Division of Oncology, Center for Applied Medical Research, Pamplona, Spain (DA, MJP, LC, JA, LMM, RP); Department of Histology and Pathology (MJP, JA, LMM) and Department of Biochemistry and Genetics (RP) School of Medicine, University of Navarra, Pamplona, Spain; Department of Oncology (JLP), Department of Pathology (MDL), Department of Thoracic Surgery (WT), Department of Pulmonary Medicine (JPdT, JJZ) Clínica Universidad de Navarra, Pamplona, Spain; Thoracic Program, Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN (PPM); Department of Medicine, University of Valencia, Valencia, Spain (CC); Department of Medical Oncology, Hospital General Universitario de Valencia, Valencia, Spain (CC); Molecular Oncology Laboratory, Fundación para la Investigación del Hospital General Universitario de Valencia, Valencia, Spain (EJL).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djt205DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3776260PMC
September 2013

Complement inhibition in cancer therapy.

Semin Immunol 2013 Feb 24;25(1):54-64. Epub 2013 May 24.

Oncology Division, Center for Applied Medical Research-CIMA, Pamplona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.smim.2013.04.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3733085PMC
February 2013

Interaction with FcγRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody.

J Immunol 2011 Aug 8;187(4):1754-63. Epub 2011 Jul 8.

Division of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton SO16 6YD, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4049/jimmunol.1101135DOI Listing
August 2011

Complement factor H is elevated in bronchoalveolar lavage fluid and sputum from patients with lung cancer.

Cancer Epidemiol Biomarkers Prev 2010 Oct 27;19(10):2665-72. Epub 2010 Aug 27.

Division of Oncology, Center for Applied Medical Research, Universidad de Navarra, Pamplona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1055-9965.EPI-10-0467DOI Listing
October 2010

Non-small cell lung cancer cells produce a functional set of complement factor I and its soluble cofactors.

Mol Immunol 2008 Jan 4;45(1):169-79. Epub 2007 Jun 4.

Lund University, Department of Laboratory Medicine, Section of Clinical Chemistry, University Hospital, S-205 02 Malmö, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molimm.2007.04.025DOI Listing
January 2008

Down-regulation of human complement factor H sensitizes non-small cell lung cancer cells to complement attack and reduces in vivo tumor growth.

J Immunol 2007 May;178(9):5991-8

Division of Oncology, Center for Applied Medical Research, School of Medicine, University of Navarre, Pamplona 31008, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4049/jimmunol.178.9.5991DOI Listing
May 2007